Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 3/20 | 0.34 |
| ▸ | GLS | O94925 | 2/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16439471 | 1.00 | RIPK1 (0.39) | RIPK1RAB9AALDH1A1GAAHTT | |
| SCHEMBL17078162 | 1.00 | RIPK1 (0.39) | RIPK1RAB9AALDH1A1GAAHTT | |
| SCHEMBL17078163 | 1.00 | RIPK1 (0.39) | RIPK1RAB9AALDH1A1GAAHTT | |
| SCHEMBL8863514 | 0.93 | ALDH1A1 (0.41) | RIPK1RAB9AALDH1A1GAAHTT | |
| SCHEMBL8863508 | 0.93 | ALDH1A1 (0.41) | RIPK1RAB9AALDH1A1GAAHTT | |
| SCHEMBL8863509 | 0.93 | ALDH1A1 (0.41) | RIPK1RAB9AALDH1A1GAAHTT | |
| SCHEMBL16439759 | 0.84 | ALDH1A1 (0.36) | RIPK1RAB9AALDH1A1GAAHTT | |
| SCHEMBL17078141 | 0.84 | ALDH1A1 (0.36) | RIPK1RAB9AALDH1A1GAAHTT | |
| SCHEMBL17800512 | 0.84 | ALDH1A1 (0.36) | RIPK1RAB9AALDH1A1GAAHTT | |
| SCHEMBL17078139 | 0.84 | ALDH1A1 (0.36) | RIPK1RAB9AALDH1A1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116862-B1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10138255-B2 | Piperazine derivatives as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-11-27 | — | — | US | disclosed |
| US-9840478-B2 | Piperazine derivatives as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170073354-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20160159752-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073354-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | PREP, CTSZ, PEPD | RIPK1 2023/4885RAB9A 2725/4885ALDH1A1 955/4885 |
| US-10138255-B2 | Piperazine derivatives as HIV protease inhibitors | PREP, CTSZ, PEPD | RIPK1 2023/4885RAB9A 2725/4885ALDH1A1 955/4885 |
| US-20160159752-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | PREP, CTSZ, PEPD | RIPK1 1284/4885RAB9A 2989/4885ALDH1A1 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.